Study: SPECT biomarker assessment could aid ovarian cancer treatment

09/18/2013 | MolecularImaging.net

A study in the Journal of Nuclear Medicine suggests that using SPECT to assess expression of vascular cell adhesion molecule-1 may help predict therapeutic response and possibly improve outcomes for patients with metastatic ovarian cancer. Among 32 patients assessed with SPECT imaging, researchers found that VCAM-1 expression was present in 15% of women after chemotherapy, compared with 72% of those who only received surgery. "[T]hese observations indicate that in addition to the presence of VCAM-1 at the earliest stages of peritoneal spread (i.e., stage II patients with secondary implants), expression is responsive to treatment," researchers wrote.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC